Business Context and Reporting Period
Company: Novo Nordisk A/S
Filing Type: Form 6-K (Report of Foreign Private Issuer)
Date: November 13, 2025
Context: This filing announces a change in the candidate slate for the upcoming Extraordinary General Meeting scheduled for November 14, 2025. Mikael Dolsten, recently Head of R&D at Pfizer, has withdrawn his candidacy for the Board of Directors due to personal circumstances unrelated to the company.
Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This document is a corporate governance announcement and does not contain financial performance data.
Material Changes
- Board Candidacy Withdrawal: Mikael Dolsten will not seek election as a Board member or observer.
- Nomination Strategy: The Novo Nordisk Foundation and Novo Holdings A/S will not propose a replacement candidate for the November 14, 2025 meeting.
- Future Nominations: The incoming Board is tasked with identifying and nominating two additional candidates (plus Helena Saxon) for the Annual General Meeting on March 26, 2026.
Outlook, Risks, and Management Commentary
Management Commentary: The company confirmed that Dolsten's withdrawal is due to personal reasons and not related to Novo Nordisk A/S or the Novo Nordisk Foundation.
Board Composition: If all remaining proposed candidates are elected, the Board will consist of Lars Rebien Sørensen (Chair), Cees de Jong (Vice Chair), Britt Meelby Jensen, Kasim Kutay, Stephan Engels, Elisabeth Dahl Christensen, Liselotte Hyveled, Mette Bøjer Jensen, and Thomas Rantzau.
Risks/Contingencies: No specific financial risks or contingencies are detailed in this filing.
Key Facts for Investor Verification
- Verify the exact date of the Extraordinary General Meeting (November 14, 2025) and the Annual General Meeting (March 26, 2026).
- Confirm the final list of Board candidates standing for election at the November 14 meeting as per the October 21, 2025 convening notice.
- Monitor future announcements regarding the two new Board candidates to be nominated by the incoming Board for the 2026 AGM.
- Note that this filing contains no financial results; refer to the most recent Form 20-F or quarterly reports for financial data.